In patients with chronic HCV genotype 2 or 3 infection receiving peginterferon and ribavirin, ITPA variants encoding reduced ITPase activity were found in approximately one-third of patients and were associated with reduced relapse risk following antiviral therapy despite lower plasma ribavirin concentrations (2). Here, ITPA is linked to infection.